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The Cre/lox system is a powerful tool for targeting therapeutic eﬀectors in a wide variety of human disorders. I review a Cre/lox
Wnt-targetedsystemthathasshownpromiseagainstWnt-positivecolorectalcancercelllines.InadditiontoWnt-speciﬁctargeting
of cell death inducers, the modular nature of this gene therapy model system can be exploited by designing positive and negative
feedbackloopstoeitheramplifyorinhibitWntactivityforexperimentalortherapeuticbeneﬁt.Idiscussthestructuralcomponents
and performance parameters of the system, the implication of these ﬁndings with respect to cancer stem cells, as well as the general
applicability of this system to any disorder characterized by diﬀerential gene expression. I also consider the issue of gene delivery
as well as in vivo testing requirements necessary for the further characterization and development of this system.
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1.Introduction
Wnt signaling is characterized by the stabilization of active,
dephosphorylated β-catenin, which, when complexed with
the T-cell factor/lymphocyte enhancer factor (Tcf-Lef) fam-
ily of transcription factors, upregulates the expression of
genes whose promoters contain Tcf/Lef-binding sites [1–6].
As a result of mutations in the adenomatous polyposis coli
(APC)o rβ-catenin genes, the majority of human colorectal
cancers (CRCs) exhibit constitutive Wnt pathway activity,
which has been implicated as a crucial step in the initiation
and development of colonic tumorigenesis [7–9]. Hyper-
activationofWntactivity,whichcanbeachievedbyexposure
of CRC cells to inhibitors of histone deaceylases (HDACis)
such as butyrate, induces apoptosis of these cells and thus
may constitute an important preventative and therapeutic
strategy against CRC [10]. However, in some cases, hyper-
activation of Wnt activity may not be the most eﬃcient
treatment of choice. CRC cells can develop resistance to
HDACis; thus, in some patients, early stage CRCs may be
resistant to the eﬀects of butyrate derived from dietary ﬁber
[11]. In addition, novel therapeutic strategies are essential
for advanced/metastatic CRC. In general, the life expectancy
for individuals with advanced CRC is only ∼2y e a r s[ 12].
Furthermore, in many advanced cases, surgical intervention
is no longer possible, and even where surgery is performed,
methodologies to ensure full eradication of neoplastic cells
andtosuppressrecurrencewouldbedesirable.Analternative
strategy against CRC is the use of CRC-targeted gene therapy
methodologies, particularly those targeting aberrant Wnt
signaling activation.
Gene therapy approaches for CRC [13] have utilized
genes (a) inducing cell death [14–22], (b) encoding for
enzymes converting prodrugs to their active forms [23–
26], and (c) necessary for viral replication, which kills neo-
plastic cells [27, 28]. Cancer-speciﬁc gene therapy depends
on diﬀerences in gene expression between neoplastic and
normal cells; therefore, expression of a gene must be both
speciﬁc to abnormal cells and strong enough to eﬃciently
inhibit cell proliferation or induce cell death. Wnt-targeted
therapeutic expression, in which expression and activity
of the relevant gene product occurs speciﬁcally in Wnt-
positive cells, has been successfully demonstrated [13, 21,
25, 27, 28]. This approach is particularly useful in CRC,
since the majority of CRCs exhibit deregulated Wnt activity
and the vast majority of normal colonic cells are Wnt
negative. Therefore, Wnt-speciﬁc expression of therapeu-
tic genes would direct therapeutic activity to the Wnt-
positive cancer cells while sparing the bulk of the normal
cells.2 Journal of Biomedicine and Biotechnology
However, studies on utilizing Wnt-targeted therapeutic
expression have been limited in that they did not undertake a
systematicanalysisof the factorsinﬂuencing the eﬀectiveness
and speciﬁcity of Wnt-mediated gene therapy. For example,
CRCcellsintrinsicallyvaryintheirlevelsofWntactivity[29–
35]. Variability in Wnt activity is likely an in vivo property
of CRCs which may complicate Wnt-directed gene therapy.
Despitethis, Wnt-targetedtherapeuticgeneexpression holds
greatpromiseforanti-CRCgenetherapyapproaches[21],by
speciﬁcally inducing cell death in Wnt-expressing malignant
colonic cells, while sparing normal cells. Further, given that
Wnt deregulation is one of the earliest events in colonic
tumorigenesis [1–6], Wnt-targeted gene therapy can also be
adapted as a preventive strategy to eliminate early neoplasms
(adenomas) that exhibit deregulated Wnt activity. However,
given the inherent variability of Wnt activity in colonic neo-
plasms, this targeting strategy requires optimization through
the use of a system that enhances both the eﬃciency and
thespeciﬁcityofeﬀectorgeneexpression.TheCre/loxsystem
[36]representssuchanapproachtoenhanceexpressionfrom
tissue- or disease-speciﬁc promoter activity.
2. Structural Components of System
The ability of the Cre/lox system to enhance expression from
speciﬁc promoters [31, 32, 37–39]h a sb e e ne x p l o i t e dt o
construct a modular Wnt-targeted therapeutic system [33].
The rationale behind the Cre/lox methodology is as follows.
The enzyme Cre recombinase excises gene sequences placed
in between tandem consensus sequences called loxP sites.
A stop cassette, ﬂanked by tandem loxP sites (“ﬂoxed”),
is placed between a strong promoter and the gene of
interest (i.e., the eﬀector). The stop cassette contains a
SV40 polyadenylation site that serves to end the mRNA at
that point and thus prevents inclusion of the downstream
eﬀector sequences in the mature transcript [[31, 36], and
references therein]. In addition, an unpaired splice donor
site and an extra translation start site is downstream of
the polyadenylation site in order to abrogate normal RNA
processing and translation in the event that ineﬃcient use
of the SV40 polyadenylation site extends the transcript past
that site [[31], and references therein]. In the absence of
Cre recombinase, the eﬀector is not expressed due to the
presence of the retained stop cassette. However, in the
presence of Cre recombinase, the stop cassette is excised,
allowing for eﬃcient eﬀector expression from the strong
constitutive promoter. Speciﬁcity is generated through the
use of a tissue/disease-speciﬁc and/or inducible promoter to
drive Cre expression. Thus, the Cre/lox approach is a “two-
step” expression system, in which speciﬁcity of expression
at the initial Cre expression step allows for high-level,
eﬃcient expression at the secondary eﬀector expression step
(Figure 1). Because of the advantages of the Cre/lox system
in maximizing both eﬃcient and speciﬁc gene expression,
this methodology is generally superior to alternatives in
which eﬀectors are directly expressed from Wnt-sensitive
promoters [21, 34, 39]. Low levels of Cre recombinase are
suﬃcient to catalyze the excision of high concentrations of
ﬂoxed DNA sequences; therefore, expression from highly
speciﬁc promoters driving Cre recombinase expression is
ampliﬁed by the enzymatic activity of the Cre recombinase.
In most cases, the Cre and loxP/stop cassette components
of the system are in diﬀerent vectors, which are introduced
together into the cells (i.e., cotransfected). However, it is
possible to combine the two components into a single vector
as long as both transcription units are kept separate [31].
Wnt-speciﬁc expression of Cre recombinase will there-
fore result in Wnt-speciﬁc expression of the ﬂoxed gene
of interest. The ﬂoxed gene could be, for example, an
inducer of cell death. Thus, if Wnt activity is primarily
characteristicofneoplasticcells,thenWnt-speciﬁcactivation
of the Cre/lox system will drive highly speciﬁc expression of
the cell death inducer, killing cancer cells while sparing their
normalcounterparts.Themodularmodelsystemundercon-
sideration here (Figure 1) utilized a variety of Wnt-speciﬁc
promoters to drive Cre expression. Cre recombinase activity,
in turn, promoted the expression of the ﬂoxed eﬀectors,
which were a luciferase reporter, FADD or diphtheria toxin
A-chain (DT-A) cell death genes, or eﬀectors capable of
up- or downregulating Wnt activity. FADD, which induces
cell death through activation of caspase 8 as part of the
Fas-mediated apoptotic pathway [35], had been previously
used as an eﬀector in a Wnt-targeted system [21]. The
DT-A, which induces cell death by ADP ribosylation of
elongation factor 2 and irreversible inhibition of protein
synthesis, had also been established as a potent eﬀector gene
in several gene therapy systems [14–18]. Other eﬀectors
that were utilized in this system included Lef-VP16, which
upregulates Wnt signaling [40], or dominant negative Tcf4
(DN-Tcf4),whichdownregulatesWntactivity[5].TheWnt-
speciﬁc promoters consisted of minimal TK, Fos, CMV,
or TATA-box promoters coupled to either modular Cre/lox
Wnt-mediated multimerized wild-type (“TOP”) or mutant,
inactive (“FOP”) Tcf-Lef binding sites. The TOP promoters
therefore were Wnt-sensitive and directed Wnt-speciﬁc Cre
expression; the FOP promoters were insensitive to Wnt
activity and exhibited only background expression from the
minimal promoter.
ApromoterlessCreconstructservedasanegativecontrol
(Figure 1).
The following example illustrates how this system would
work in principle. Assume that the eﬀector vector contains
ﬂoxed luciferase reporter. The Cre expression vectors would
be in other separate plasmid vectors. For the purposes of
illustration, we will assume that these Cre vectors utilize the
CMV minimal promoter (TOPCMV-CRE, FOPCMV-CRE,
and the promoterless 0-CRE). The ﬂoxed luciferase vector
would be cotransfected into Wnt-positive CRC cells along
with one of the three Cre expression constructs. TOPCMV-
CRE contains the Wnt-sensitive TOP promoter containing
Tcf-binding sites. Therefore, in Wnt-positive CRC cells,
TOPCMV-CRE would express levels of Cre recombinase
suﬃcient to remove the stop cassettes from most of the
cotransfected ﬂoxed luciferase plasmids, resulting in high
levels of luciferase expression and activity. However, in
cells cotransfected with FOPCMV-CRE and the ﬂoxed
luciferase vector, very little luciferase activity is expected;Journal of Biomedicine and Biotechnology 3
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Figure 1: Schematic of the model system. Wnt signaling, which can be up- or downregulated by pharmacological or genetic modulators,
promotesexpressionfromWnt-sensitivepromoters,drivingproductionofCrerecombinase.Creexcisesstopcassettesfromﬂoxedexpression
vectors, allowing for production of eﬀectors. Included in the eﬀectors are genes that can positively or negatively feed back to inﬂuence Wnt
activity and, hence, Cre expression. This model system can be generally applicable to any human disorder characterized by aberrant gene
expression involving disorder-speciﬁc transcription factors, reproduced as per copyright agreement from [33].
the FOP promoter, containing mutant binding sites, is not
activated by Wnt signaling. Therefore, very low levels of Cre
recombinase are produced by the weak background activity
of the minimal CMV promoter fragment of FOPCMV-CRE.
0-CRE, lacking a promoter, should not express any Cre at all.
There are several issues of importance with respect to
the structural design and performance parameters of this
modular system. In human patients, the environment in
which this therapy system would operate would consist of
both aberrant Wnt-positive cells and normal Wnt-negative
cells (eﬀects of this system on normal Wnt-positive cells are
discussed below). However, CRC cell lines used to test the
system in vitro are, typically, Wnt-positive only. To test the
speciﬁcity of the system in vitro, it is necessary to mimic
the lack of Wnt activity of normal cells in neoplastic CRC
cells that possess constitutively activated Wnt signaling. This
was addressed by utilizing the TOP/FOP promoter system
(Figure 1). Cre expression driven by TOP promoters will
be Wnt-speciﬁc; hence, eﬀector expression resulting from
Cre excision of the stop cassette will also be Wnt-speciﬁc.
Cre expression from the mutant FOP promoters will be
insensitivetoWntactivity;therefore,incellstransfectedwith
FOP-CRE and ﬂoxed eﬀector constructs, the expression of
the eﬀector will also be insensitive to Wnt activity. Note
the similarity between (a) introduction of TOP-CRE and
ﬂoxed eﬀector into Wnt-negative normal cells in vivo and
(b) introduction of FOP-CRE and ﬂoxed eﬀector into Wnt-
positive CRC cell lines in vitro; in both cases, Cre expression
and consequent eﬀector activity will be low or nonexistent.
In the ﬁrst case (i.e., example a), this is because there is no
Wnt activity in the normal cells to stimulate Cre expression.
In the second case (i.e., example b), Wnt activity is present,
but the mutant FOP promoter is insensitive to this Wnt
activity and very little CRE is produced. Therefore, the lack
of eﬀector expression from the FOP-CRE constructs in Wnt-
positive cells in vitro models the lack of eﬀector activity
which would be exhibited by the wild-type TOP promoters
in Wnt-negative cells in vivo.
Second, the terms “eﬃciency” and “speciﬁcity” must be
deﬁned for this system. Eﬃciency refers to the maximization
of eﬀector expression; on the other hand, speciﬁcity refers
to targeting eﬀector expression in a Wnt-speciﬁc manner. In
vivo, optimizing eﬃciency and speciﬁcity would mean the
highest possible eﬀector expression in targeted Wnt-positive
cells coupled with the least possible eﬀector expression in
Wnt-negative cells. In vitro, maximal eﬃciency of eﬀector
expression will be observed with the wild-type TOP promot-
ers driving Cre expression; speciﬁcity will be observed in the
diﬀerence between eﬀector expression resulting from use of
the TOP versus FOP promoters.
Third, it is crucial to understand the fundamental
diﬀerences in the dynamics of a luciferase reporter system
compared with a cell kill model. In the speciﬁc case of
luciferase reporter assays, I have observed that the activity of
the reporter generally correlates with the level of expression
ofthereportergeneinalinearfashion(Figure 2(a));thus,the
more luciferase produced, the higher the luciferase activity
[33]. In contrast, once a level of FADD or DT-A suﬃcient to
kill cells with ∼100% certainty is reached, further expression
of that gene is superﬂuous (Figure 2(b)). A given cell can
only be killed once; expression of FADD or DT-A beyond
the level required to kill the cell cannot further increase the
eﬃciencyofcelldeath.Therefore,forcellkill,aroughlylinear
correlation between expression and activity exits only within
a relatively narrow range of eﬀector expression. At the lower
end of the range of eﬀector expression, eﬀector levels are4 Journal of Biomedicine and Biotechnology
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Figure 2: Reporter activity diﬀers from cell death induction. (a)
Graph modeling the relationship between luciferase expression and
luciferase reporter activity, within the linear range of detection
of a luminometer; an essentially linear relationship is depicted.
(b) Graph modeling the relationship between concentration of
the cell death inducer FADD and probability of cell death for
cells in the transfected cell population. An essentially sigmoidal
curve is depicted, as the probability of cell death cannot exceed
100% regardless of increasing levels of FADD. For both (a) and
(b) arbitrary units of measurement are shown for the purposes of
illustration.
too low to result in any detectable cell kill. At higher levels
of eﬀector expression, the probability of cell kill reaches ∼
100%; beyond that level of expression, saturation of eﬀector
activity occurs.
On the other hand, cell death, while also quantitative, is
a “yes or no” binary measurement, and the probability of
death of any given cell is intrinsically saturable; increasing
eﬀector expression beyond what is required for ∼100%
cell kill will have no further eﬀects. Therefore, a graph
of luciferase eﬀector expression versus luciferase activity
is expected to result in an upwardly sloping straight line
(Figure 2(a)), while a graph of FADD eﬀector concentration
versus probability of cell kill is expected to level oﬀ at higher
eﬀector concentrations, producing an essentially sigmoidal
curve (Figure 2(b)). This would suggest that using reporter
systems to model cell death may yield misleading ﬁndings,
since the dynamics of these eﬀectors are diﬀerent.
Gene therapy systems for CRC have been developed in
whicheﬀectorsaredirectlylinkedtoWnt-speciﬁcpromoters,
without the additional step of Cre-mediated ampliﬁcation of
expression [21, 34]. Although the eﬃcacy of these systems
has been demonstrated, they lack the ﬁne control of eﬀector
expression exhibited by the more complex Cre/lox system
[33, 34]. This ﬁne control is made possible by the ampliﬁ-
cation of eﬀector expression that results from the catalytic
activity of Cre recombinase. Theoretically, four molecules
of Cre recombinase can repeatedly catalyze the excision
of stop cassettes from many molecules of ﬂoxed eﬀector;
thus, relatively small amounts of Cre produced from low
concentrations of Cre-expressing vectors can result in high
levels of therapeutic eﬀector gene expression. It is therefore
possible to titrate the Cre vector to low concentrations
that minimize nonspeciﬁc background expression, while
maintaining high levels of speciﬁc, disease-targeted eﬀector
expression. Separating Wnt-speciﬁcity (Cre vector) from
strong eﬀector expression (ﬂoxed vector) allows the Cre/lox
system to combine high speciﬁcity with high eﬃciency. On
the other hand, direct expression of the therapeutic gene
bypassestheCre-mediatedampliﬁcationstep.Here,highlev-
els of eﬀector expression will require higher concentrations
of the gene therapy vector, resulting in greater background
expression of the eﬀector and a consequent loss of speciﬁcity.
3. Activityof the Cre/LoxWnt Model System
TheCre/loxsystemdescribed(Figure 1)wasshowntoinduce
eﬃcient and speciﬁc Wnt-targeted eﬀector activity when the
CMV minimal promoter was coupled to TOP sequences
and used to drive Cre expression, which in turn activates
FADD expression to kill the targeted cells (Figure 3). In
these experiments, a vector expressing luciferase from a
constitutive promoter was cotransfected with the Cre and
ﬂoxed eﬀector gene therapy vectors. Luciferase activity was
used as a marker of cell transfection to determine the relative
number of remaining cells.
In these experiments, cell type diﬀerences were observed;
eﬃcient and speciﬁc cell kill in the HCT-116 CRC cell
line required cotreatment with both butyrate and lithium
chloride, while SW620 CRC cells exhibited eﬃcient cell kill
in both the presence and absence of butyrate [33]. These
diﬀerences between HCT-116 and SW620 CRC cells in
response to Wnt-speciﬁc Cre/lox-mediated eﬀector activity
suggest that a given genetic therapeutic strategy may not be
optimal for all CRCs. HCT-116 and SW620 CRC cells may
therefore represent subtypes of CRCs in vivo which would
exhibit diﬀerential responses to Wnt-targeted gene therapy.
This modular Cre/lox system was able to rescue subop-
timal concentrations of transfected Cre expression vectors,
and induce eﬃcient cell death, by utilizing ﬂoxed Lef-VP16
alongside ﬂoxed FADD (Figure 4)[ 33]. In the absence of
ﬂoxed Lef-VP16, very low levels of Cre expression could not
suﬃciently activate FADD expression to induce cell death.
In the presence of ﬂoxed Lef-VP16, the low levels of Cre
expression activated Lef-VP16 expression. Lef-VP16 bound
to the TOP promoter and, in turn, induced higher levels
of Cre expression. These greater levels of Cre expression
resulted in more eﬃcient expression of FADD and increased
cell death.Journal of Biomedicine and Biotechnology 5
Thus, given that the ﬂoxed Lef-VP16 was shown to act in
positive feedback fashion to enhance Wnt activity in a Wnt-
speciﬁcmanner,thesedatasuggestthatweakWntsignalscan
be ampliﬁed by an Lef-VP16 eﬀector, resulting in eﬃcient
and Wnt-speciﬁc eﬀector expression over a wide range
of endogenous Wnt activity levels. Alternatively, utilizing
ﬂoxed DN-Tcf as the eﬀector, Wnt-speciﬁc down regulation
of Wnt activity, constituting a negative feedback system,
was demonstrated (Figure 5)[ 33]. Downregulation of Wnt
activitymayusefulforCRCresistanttotheabilityofbutyrate
to enhance Wnt activity and apoptosis [10, 11, 30].
4.ModularNatureofSystem
A novel feature of the Wnt-targeted Cre/lox system is
its modular nature. This is best represented by Lef-VP16
and DN-Tcf4 as eﬀectors to up- or downregulate Wnt
signaling in a Wnt-dependent manner (Figures 4 and 5).
Positive or negative feedback loops can be applied to any
signaling pathway which generates aberrant gene expression,
by creating a ﬂoxed dominant negative form of a key
transcription factor of that pathway (negative feedback
regulation) or by fusing the DNA binding domain of a
transcription factor to VP16 (positive feedback regulation).
One objective of negative feedback regulation could include
directly inhibiting an aberrantly activated signaling pathway
for therapeutic eﬀect; this self-downregulation method can
be applied to any situation in which a dominant-negative
protein inhibits a signaling pathway essential for cell growth
and/or survival. Alternatively, positive feedback regulation
could entail stimulating the relevant signaling pathway in
o r d e rt oe n h a n c et h ee ﬃciency of the Cre/lox system,
resulting in increased eﬀector expression. Another aspect of
this modular system is the ability to use aberrant activation
of one signaling pathway to induce targeted activation of a
more general, second signaling pathway. Thus, for example,
a cancer speciﬁc signaling pathway can be used to drive
Cre recombinase expression, which would then activate a
transcription factor (the ﬂoxed eﬀector) involved in a second
signaling pathway, for example, inducing diﬀerentiation or
some other desired eﬀect. In summary, virtually any phys-
iological process characterized by speciﬁc gene expression,
and by deﬁned transcription factors, can be (therapeutically)
modulated by the Cre/lox system. In particular, positive and
negative feedback loops, made possible with this modular
system, are well suited for “ﬁne tuning” transcriptional
activity, leading to more precise and tightly controlled
ampliﬁcation or repression of relevant signaling pathways.
5. Safer Gene Delivery Options
The design of an eﬀective gene therapy vector system is only
part of the requirement for eﬀective therapy; an eﬃcient and
safe delivery system must also be designed and evaluated.
Viral vectors have been the primary method for delivering
genes into host cells and achieving gene expression; how-
ever, viral vectors suﬀer from several drawbacks, including
toxicity, immunogenicity, and the potential replication of
competent viruses. Furthermore, several deaths have been
likely associated with the use of viral vectors in gene
therapy trials [41–43]. Thus, the development of nonviral
gene therapy delivery systems is necessary to make gene
therapy approaches safer and more practical for the human
patient. An eﬀective nonviral vector must eﬃciently enter
andtransfectacellwithoutstimulatinganimmuneresponse,
and must also be nontoxic. Biodegradable nanoparticles are
generally superior to other nonviral vectors, since they are
comparable in size to viruses and are therefore internalized
in a similar manner, while being large enough to carry
genetic material such as plasmid DNA [44]. L-tyrosine
polyphosphate (LTP) nanoparticles have been produced and
have shown considerable promise in initial studies [44].
Plasmid DNA is released from these nanoparticles over
a period of 14 days, optimal for intracellular delivery of
therapeutic gene sequences, and these nanoparticles exhibit
a lack of toxicity during this time period [44]. Further, using
known coupling techniques [45–47], nanoparticles can be
complexed with antibodies, thus targeting gene delivery to
cells expressing speciﬁc cell surface markers, enhancing both
theeﬃcacyandsafetyofthesystem.Nanoparticlesystemsare
wellsuitedforusewiththeCre/loxsystem;LTPnanoparticles
have been tested with plasmids [44]a n dw i l lb ea b l et o
carry both the Cre and lox components of a modular gene
therapy system. Given the nontoxic nature of the this gene
delivery system, repeated and overlapping applications of
Cre/lox system-containing nanoparticles are likely to result
in signiﬁcant levels of targeted cell death with relatively low
levels of side eﬀects due to immunogenicity or toxicity.
6. Wnt-Targeted Therapy andCRC Stem Cells
Cancer stem cells are a subpopulation of neoplastic cells that
exhibit the deﬁning characteristics of stem cells: the ability to
self-proliferate and the ability to diﬀerentiate into varied cell
types. The leading theory of cancer stem cells [48] suggests
that these cells give rise to tumors and are responsible for
metastases and relapse, the latter occurring when treatment
eliminates the bulk of relatively diﬀerentiated tumor cells,
while leaving the cancer stem cell population unaﬀected. The
“migrating cancer stem cell” (MCS) concept of Brabletz et
al. [49] may be of relevance to Wnt-directed therapy. These
authors make a distinction between stationary cancer stem
(SCS) cells, which are anchored in the epithelial tissue and
do not migrate, and MCS cells, which possess the same
proliferative and diﬀerentiating potential as the SCS cells,
but exhibit a migratory phenotype. MCS cells are derived
from their stationary counterparts by acquiring a transient
epithelial to mesenchymal transition (EMT), which allows
them to disseminate. This dissemination can either be short-
range, resulting in expansion of the primary tumor, or long-
range through blood and/or lymphatic vessels, resulting
in metastases. Once established in the new location, these
cells may undergo a reversal of EMT, or a mesenchymal
to epithelial transition (MET), which reverses the growth
arrest (and resistance to apoptosis) that characterizes the
EMT phenotype. This MET ultimately results in enhanced6 Journal of Biomedicine and Biotechnology
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Figure 3: Wnt-speciﬁc SW620 cell kill. SW620 cells in a 24-well plate were transfected with 0.05μg of pGL3-Ctl, 0.5μgo fS T O P - F A D D ,a n d
(a) 0.05μg of TOP/FOPTK-CRE, (b) 0.0067μg of TOP/FOPCMV-CRE, (c) 0.1μg of TOP/FOPFos-CRE, or (d) 0.15μg of TOP/FOPTATA-
CRE, with equivalent amounts of the 0-CRE control expression vector per well, and untreated or treated with 5 mM butyrate, and assayed
for luciferase expression 48 hours later. Luciferase readings were normalized to protein concentration determined for each sample. The input
plasmids for each experiment are listed at the top of each graph. Results are from three independent experiments. Bars indicate standard
deviations, reproduced as per copyright agreement from [33].
proliferation, diﬀerentiation, and growth of the metastasis
[49].Wntactivityisintimatelyinvolved intheseprocesses,as
thissignalingpathwayhasbeenlinkedtostemcellgeneration
and maintenance [50, 51] as well as the establishment of
EMT [49]. Several Wnt target genes promote the stem cell
phenotype, among them survivin, which induces prolifera-
tion while inhibiting apoptosis; another set of Wnt target
genes, such as SLUG, L1CAM, and LAMC2, are associated
with EMT [49] .T h eﬁ r s ts e to f“ s t e m n e s s ”g e n e sa r e
expressed early in colonic tumorigenesis and likely requireJournal of Biomedicine and Biotechnology 7
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Figure 4: Positive upregulation using the modular Cre/lox system. Floxed eﬀectors can include positive upregulators of the transcriptional
activity driving Cre expression. For example, in this model system, Lef-VP16, which upregulates Wnt activity, is expressed from a ﬂoxed
vector in a Wnt activity-speciﬁc manner. The Lef-VP16 feeds back to stimulate Wnt activity, resulting in higher levels of Cre expression and,
hence, more production of the ﬂoxed eﬀectors, which includes not only the Lef-VP16 itself but also gene products resulting in, for example,
cell death. Positive feedback increases the overall eﬃciency of the system, amplifying the original transcriptional signal, and can be used to
enhance the eﬀectiveness of the system under suboptimal conditions, adapted from [33].
CRE excises the stop
cassette and allows for
expression of DN-Tcf4
No CRE, no excision,
no expression of DN-Tcf4
Inhibition
Basal Wnt
activity (TOP/FOB)
Basal Wnt
activity (TOP/FOB)
TOP CRE FOP CRE
CMV-β-actin promoter Stop DN-Tcf4
DN-Tcf4 No expression
DN-Tcf4 blocks Wnt activity,
downregulates T/F ratio
Figure 5: Negative downregulation using the modular Cre/lox system. Floxed eﬀectors can include negative repressors of the transcriptional
activity driving Cre expression. For example, in this model system, DN-Tcf4, which inhibits Wnt activity, is expressed from a ﬂoxed vector
in a Wnt activity-speciﬁc manner. The DN-Tcf4 feeds back to repress Wnt activity in a Wnt activity-speciﬁc manner. Generalized systems of
this nature can be applied to other disorders in which constitutive high activation of cell signaling causes disease, adapted from [33].
low levels of constitutive Wnt activity; the expression of
these genes is maintained throughout the process of tumori-
genesis [49]. However, EMT-related genes are transiently
upregulated in the invasive-front cells; these are likely MCS
cells that express high levels of nuclear beta-catenin and
Wnt activity. EMT-related gene expression is subsequently
downregulated during MET, leading to the diﬀerentiation
of cells which exhibit lower levels of nuclear beta-catenin
[49]. Wnt-targeted gene therapy should therefore represent
a reasonable approach for targeting CRC stem cells, since
these cells both (a) exhibit Wnt signaling and (b) are
apparently more dependent on Wnt activity for maintenance
and progression compared to the more diﬀerentiated cells
within the tumor. The fact that MCS cells exhibit high levels
of nuclear beta-catenin suggests greater levels of Wnt activity
in these cells. Therefore, it may be possible to design Wnt-
targeted “calibrated” so that they produce eﬀector output
in the presence of high, aberrant Wnt activity in MCS cells
but not in the presence of lower levels of Wnt activity that
characterize normal stem cells in the colonic crypt. This8 Journal of Biomedicine and Biotechnology
approachwouldtargetthedangerouscancerstemcells,while
leaving normal stem cells relatively unaﬀected. Further, Wnt
target genes associated with EMT can be utilized to target
therapeutic expression to CRC stem cells.
7. In VivoCre/LoxFunction,
Differences with InVitro Evaluation
In general, successful gene therapy for the elimination of
abnormality (e.g., neoplastic cells, abnormal gene expres-
sion, and expression of mutant proteins) is more diﬃcult
to achieve than is the restoration of diminished normal
function.Intheformercase,invivotherapeuticsuccessoften
requires ∼100%eliminationoftheabnormality(e.g., ∼100%
elimination of neoplastic cells, to prevent recurrence), while,
in the latter case, even partial restoration of normal gene
expression and normal function may be suﬃcient to alleviate
or eliminate disease.
There are signiﬁcant diﬀerences between gene therapy
(including Cre/lox) approaches for the in vitro (cell culture)
and in vivo (animal models, humans) situations. Any given
in vitro experiment usually utilizes a single cell type growing
as a monolayer, while in vivo work deals with whole animals
with integrated organ systems and a wide variety of tissue
types arranged in a complex three dimensional architecture.
Further, a given cell type in culture may be either normal
or abnormal (e.g., cancer cell line), but an in vivo disease
model, or human patient, will most often consist of a small
fraction of abnormal cells within a great mass of normal
tissues. Thus, issues of targeting and side eﬀects are more
important in vivo than in vitro. CRC, a disease for which
Wnt-targeted therapeutic expression would be particularly
eﬀective, illustrates these points.
For example, in contrast to a CRC cell line in culture, an
in vivo tumor consists of a mass of neoplastic cells within
an organism that most likely otherwise consists of healthy
tissues and organ systems. Not all CRCs are Wnt positive,
although the great majority is; those that are not will require
genetic targeting other than that of Wnt activity. Of those
CRCs that are Wnt positive, the levels of Wnt signaling may
vary, requiring diﬀerent approaches for Wnt-targeted gene
therapy. As an in vitro analogy, SW620 cells exhibited eﬃ-
cient and speciﬁc Wnt-targeted cell kill by Cre/lox-mediated
FADD expression in the presence or absence of butyrate,
while HCT-116 cells required cotreatment with butyrate and
lithium chloride to allow for eﬃcient and speciﬁc Cre/lox-
mediated cell death [33]. Even more fundamentally, normal
cells, including intestinal stem cells, exhibit low basal Wnt
activity levels. Therefore, given the eﬃciency of the Cre/lox
system to induce gene expression, the possibility exists that
a Wnt-targeted system may result in oﬀ-target normal cell
death,inducingunwantedsideeﬀects.Tosomeextent,itmay
be possible to design relatively insensitive Wnt responsive
promoters, so that Cre expression will only occur at a
relatively high threshold level of Wnt activity exhibited by
CRCcells,butnotexhibitedbytheweaklyWnt-positivestem
cells of intestinal crypts.
However, it is possible that some degree of oﬀ-target cell
death of normal Wnt positive cells is inevitable with a Wnt-
targeted gene therapy system. Side eﬀects from such treat-
ment may be analogous to that observed with chemotherapy
or radiation and can be acceptable if signiﬁcant therapeutic
beneﬁt occurs. As part of in vivo testing of the Wnt-targeted
Cre/lox system in mouse models of CRC, it will be important
to monitor side eﬀects of treatment, particularly focused
on cells/tissues known to require basal Wnt signaling (e.g.,
intestinal stem cells, hair follicles). Wild-type mice should
be evaluated alongside their cancer model counterparts,
to determine if Wnt-targeted eﬀector expression results in
unwanted morbidity and/or mortality, and to what extent
this occurs. The speciﬁc sites of these oﬀ target eﬀects
must be identiﬁed; determination of the mechanism(s) by
which these side eﬀects occur will assist in developing
approaches to minimize oﬀ targeting and its associated
morbidity/mortality. Wnt-targeted therapy must be shown
to exhibit a sound safety proﬁle in mouse models before
clinical trials can begin in human subjects.
It also remains to be determined whether the more
complex positive and negative feedback loops described in
Figures 4 and 5 of the current review would be as eﬀective in
vivo as they are in vitro. To eﬀectively create such feedback
systems in vivo will require delivery of all components of the
Cre/lox system into the same cells at the same time, which
is in large part a function of the delivery methods utilized.
Cotransfectioninvitroisnotdiﬃcult,butthesameapproach
in vivo may require that all components of the system should
be incorporated into the same delivery vehicle.
Delivery of the gene therapy vectors (see also Section 5,
above) is another area in which in vitro and in vivo
experiments are expected to signiﬁcantly diﬀer. Cells in
culture can be transfected by means not feasible or safe
for whole organisms. Viral delivery is eﬀective both in
vitro and in vivo; however, eﬀe c t i v ev i r a lg e n ed e l i v e r y
into a cell culture monolayer will be signiﬁcantly easier
to achieve than into most, or all, of the cells of a solid
tumor in vivo. Methods for introducing viral vectors more
directly into the targeted tissue of mouse models, such as
injection at the tumor site, may not be feasible or desirable
in human patients. Systemic application (e.g., i.v.) of the
viral vectors is the most likely clinical approach, but viral
vectors also present safety problems for human subjects [41–
43]. Nonviral delivery systems may eventually represent an
eﬀective solution to many of these problems. For example,
nanoparticles are not only non-immunogenic and nontoxic
[44] but can be complexed with antibodies to cell surface
antigens that are relatively speciﬁc to cancer cells, improving
targeting eﬃciency and speciﬁcity. Nonviral gene delivery
vehicles can be designed to encapsulate multiple vectors at
the same time, allowing for more eﬃcient introduction of
all system components concomitantly into target cells. For
gastrointestinal disease, oral formulations of these nonviral
delivery vehicles can be designed to target release at the
appropriate point in the gastrointestinal tract. In summary,
much work is required for designing delivery systems
for in vivo gene therapy, particularly delivery approaches
appropriate for human subjects.Journal of Biomedicine and Biotechnology 9
In vivo testing of the modular, Wnt-targeted Cre/lox
system is expected to be feasible given that the Cre/lox
system has a long history of in vivo use, particularly in
mice. The role of the Cre/lox system in creating conditional
gene knockouts in transgenic mice is well known. For
example, and relevant to this review’s emphasis on CRC,
the Fearon group has created a mouse model in which
Cre/lox-mediated knockout of the Apc allele in an intestinal-
targeted manner resulted in intestinal neoplasms, including
adenoma-carcinoma progression in the large bowel [52].
In general, the Cre/lox system has shown the ability to
direct highly speciﬁc and targeted gene expression in mouse
models.
Of greater relevance to the current review, the Cre/lox
system has shown in vivo therapeutic eﬃcacy in various
mouse models of human disease. Dopamine deﬁcient mice
have been created by the functional knockout of the Tyrosine
hydroxylase (Th) gene through insertion of ﬂoxed stuﬀer
sequences. These mice exhibit fatal neurological disorders
that can be rescued by Cre-mediated targeted expression of
Th in the mouse brain [53]. Activated hepatic stellae cells
are involved in extracellular matrix deposition subsequent
to liver injury and thus represent a target for antiﬁbrotic
therapy [54]. The collagen 1A2 gene promoter driving Cre
expression was shown to target eﬀector gene expression and
activity in activated hepatic stellae cells, with limited non-
speciﬁc expression in hepatocytes [54]. Targeted clearance of
activated hepatic stellae cells was achieved in vivo, in mouse
models of liver injury, utilizing collagen 1A2 promoter-Cre
coupled to a ﬂoxed HSV-1 thymidine kinase eﬀector gene,
in combination with ganciclovir treatment [54]. Thymidine
kinase activates ganciclovir via phosphorylation, allowing
for targeted cell death; the combination of Cre-mediated
thymidine kinase expression and ganciclovir treatment is a
typical model of Cre/lox-mediated prodrug activation [39].
Carcinoembryonic antigen (CEA) is overexpressed in
gastrointestinal cancer; Ueda et al., utilizing a ﬂoxed
lacZ eﬀector under the control of Cre expressed from a
CEA promoter, demonstrated in vivo tissue speciﬁc lacZ
expression [38]. In this and subsequent studies from this
research group, adenovirus was used as the delivery vehicle
to introduce the Cre/lox vectors into mouse models of
gastrointestinal cancer. Thus, Ueda et al. created a gene
therapy model system in which CEA promoter-Cre activity
controlled expression of ﬂoxed cytosine deaminase, targeting
conversion of the nontoxic prodrug 5-ﬂuorocytosine to 5-
ﬂuorouracil in CEA expressing cells. This system was initially
demonstrated to be eﬃcacious against an orthotopic gastric
carcinoma mouse model [32] and was later applied to
CRC [55]. Here, an orthotopic mouse model of CRC was
developed which progresses to liver metastases, similar to
what is observed in advanced human CRC. Adenovirus
vectors containing CEA promoter-Cre and ﬂoxed cytosine
deaminase were injected into the abdominal cavity of the
mice, followed by treatment with 5-ﬂuorocytosine [55]. This
treatment regimen completely repressed the development
of liver metastases, reduced primary tumor burden, and
extended mouse survival [55], clearly demonstrating in
vivo eﬃcacy of Cre/lox gene therapy in this mouse model.
These ﬁndings were similar to that of an earlier study that
demonstratedeﬀectiveCre/lox-mediatedtherapeuticactivity
against peritonitis carcinomatosa caused by implantation of
CEA expressing LoVo CRC cells in mice [39]. Adenovirus
vectors containing CEA promoter-Cre and ﬂoxed HSV-1
thymidine kinase were coinjected into the mice via the
intraperitoneal route, followed by treatment with ganci-
clovir. This treatment regimen markedly reduced tumor
burden in the mice, without signiﬁcant weight loss [39].
The in vivo advantage of the Cre/lox ampliﬁcation step, as
comparedtoweakdirectexpressionofthymidine kinase,was
also clearly demonstrated in this study; Cre/lox-mediated
thymidine kinase expression reduced tumor weight to 22%
of that observed with direct thymidine kinase expression
from the CEA promoter [39]. Furthermore, the Cre/lox
system enhanced speciﬁcity of expression as well as strength
of expression. Thus, an adenoviral vector nonspeciﬁcally
and directly expressing thymidine kinase from a strong
constitutive promoter resulted in death of the mice from side
eﬀects such as diarrhea, weight loss, and liver malfunction
[39]. These ﬁndings underscore the ability of the Cre/lox
system to leverage Cre mediated ampliﬁcation of highly
speciﬁc gene expression, resulting in robust and speciﬁcally
targeted in vivo therapeutic eﬀects that avoids excessive oﬀ-
targeting and associated morbidity/mortality.
An adenoviral Cre/lox system was also successfully used
to direct therapeutic gene expression of HSV-1 thymidine
kinase in astrocytomas, which, when combined with ganci-
clovir, signiﬁcantly reduced tumor growth [56], extending
the practical utility of viral-delivered Cre/lox therapeutics
to another cancer type. Therefore, Cre/lox-mediated gene
therapy has clearly shown eﬃcacy in mouse models, albeit
with adenoviral delivery systems not well suited for human
use [41–43]. The challenge is to combine various gene
therapy approaches (e.g., modular Wnt-targeted Cre/lox
systems) with nonviral delivery vehicles for evaluation in
mouse models (e.g., models of CRC) in advance of human
clinical trials.
8. Summary of PracticalIssues,
Utility,and FutureInVivoTesting
Wnt-targeted gene therapy systems can be of particular
practical utility in the treatment of advanced/metastatic
CRC, and/or, as an adjunct or an alternative to surgery; they
may also be particularly attractive as an alternative to total
colonectomy. In addition, a gene therapy approach could be
useful in the treatment of patients with familial adenomatous
polyposis coli (FAP), as an alternative to prophylactic surgery.
The modular Wnt-targeted Cre/lox system described in this
review must be tested in an animal model, focusing on
eﬃcacy and speciﬁcity, general applicability, and of course,
determination of the most eﬀective delivery system. The
APCmin m o u s ei sa ne ﬀective model of CRC initiation and
earlyprogression;thismousestrainrepresentsausefulexper-
imental tool to examine whether Wnt-targeted therapeutic
expression can suppress the initiation and growth of Wnt-
mediated intestinal neoplasms. Orthotopic mouse models of10 Journal of Biomedicine and Biotechnology
CRC are particularly useful analogues of advanced CRC and
metastasis in humans, as they often result in lymph node
and liver metastases, and thus mimic advanced stage human
disease [32, 55]. Thus, these mice can be utilized to test the
eﬃcacy of the Wnt-targeted Cre/lox therapy system against
advanced/metastatic CRC, the most likely clinical target of
this system. In addition, the eﬃcacy of this gene therapy
system against the viability of primary CRC cells in culture,
obtained from human patients after resection, should be
determinedalongwiththenecessaryrodentstudies.Itwillbe
crucialtodeterminewhetherWnt-targetedtherapeuticshave
negativesideeﬀectsonnormalcellsthatexhibit Wntactivity,
such as the stem cell compartment of intestinal crypts. Viral
and nonviral (e.g., nanoparticle) delivery systems for these
genetherapyvectorsshouldbedirectlycomparedinthesame
in vivo studies, to evaluate both eﬃciency of gene delivery as
well as safety/toxicity.
With respect to projected human use, biopsies of CRC
tissue or of colonic tissue of patients with FAP can be
evaluated for the presence of Wnt-activating mutations, as
well as for levels of nuclear, active β-catenin via immunocy-
tochemistry. Such measurements will ascertain the presence
of, and the potential level of, Wnt activity in the neoplastic
cells; determination of the presence of Wnt-activation in
the neoplastic tissues will allow for the use of Wnt-targeted
genetic therapeutics. Estimation of the level of the Wnt
activity in the cells, by analysis of active β-catenin in
the tissues, can assist in the choice of the optimal gene
therapeutic approach (e.g., cell death and/or inhibition of
Wnt activity). Optimally, a nonviral system can be utilized
to introduce the genetic material into the cells; further,
more speciﬁc targeting of the nonviral delivery system to
the neoplastic tissues can enhance eﬃcacy and speciﬁcity.
Thepresenceofparticularcellsurfacemarkersoverexpressed
in the neoplastic cells compared to normal tissues can be
determined from the biopsied tissues. Antibodies to these
cell surface markers can be complexed to nanoparticles,
targetinggenedeliverytoaberrantcellsthatarecharacterized
by the relevant cell surface marker proﬁle. Thus, careful
examination of tissue obtained from the patient can provide
informationthatwillallowfortheWnt-targetedstrategybest
suited for treating that individual’s speciﬁc neoplasm.
9. Conclusion
A Cre/lox Wnt-targeted gene therapy model system has been
developed and tested in vitro. Levels of eﬀector expression in
this system can be ﬁnely regulated by the choice of promoter
and by the use of both pharmacological and genetic factors.
Importantly, the modular nature of the system allows for a
varietyofgeneexpressioncircuitstobeestablished,including
positive and negative feedback loops. Further, it may be
possible to utilize a promoter that has a speciﬁc threshold
of activation, so that the eﬀe c t o rg e n ew i l lo n l yb ee x p r e s s e d
in the presence of the higher levels of Wnt activity found
in MSC cells, leaving normal colonic stem cells unaﬀected.
The modular nature of this system suggests that it may
be generally applicable to a wide variety of disease states
that exhibit diﬀerential gene expression through aberrant
signaling pathways. To complement this system, it will
be important to develop nonviral methods that combine
eﬃciency of gene delivery with a superior safety proﬁle. In
vivo testing, including determination of eﬀective and safe
delivery systems, is the logical next step in furthering the
development of this system. The ﬁndings of these projected
in vivo studies will advance our understanding of the theo-
retical and practical issues related to Wnt-targeted anti-CRC
genetic therapeutics and provide the foundation for further
development leading to clinical trials in individuals with
late stage/metastatic CRC. Modular gene therapy systems
may eventually represent a major and novel advance in the
treatment of advanced cancer.
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